Introduction

  1. Hypertensive emergency is characterized by SBP >180 mmHg or DBP >120 mmHg with evidence of acute target-organ damage.
  2. Rapid blood-pressure lowering with intravenous antihypertensives is warranted to prevent further organ damage.
  3. Patients with aortic dissection, eclampsia/preeclampsia, pheochromocytoma crisis, or intracranial hemorrhage have time-critical targets.
  4. No single agent has a proven mortality benefit; choose by the target organ(s) involved, comorbidities, and time-to-target.

Treatment in Selected Comorbidities

ConditionBP goalPreferred agents
Acute aortic dissectionSBP <120 mmHg within 20 minEsmolol, labetalol, nicardipine, nitroprusside
Eclampsia / preeclampsiaSBP <140 mmHg within 1 hrNicardipine, labetalol, hydralazine
Pheochromocytoma (catecholamine excess)SBP <140 mmHg within 1 hrNicardipine, phentolamine*
Intracranial hemorrhageSBP <160 mmHg within 6 hrNicardipine, labetalol
Acute ischemic strokePre-alteplase: <185/110 mmHg
Post-alteplase: <180/105 for 24 hr
No thrombolytic: reduce SBP ~15% over 24 hr**		Nicardipine, labetalol

*Phentolamine for catecholamine excess. **Thresholds shown are for thrombolysis (alteplase) eligibility; post-thrombectomy BP evidence (OPTIMAL-BP) is discussed separately in the Evidence section.

Pharmacology

MedicationClassOnsetDurationDosingClinical pearls
First-line agents
NicardipineCalcium channel blockerIV: 5–10 minIV: 2–6 hrInitial: 5 mg/hr
Titration: 2.5 mg/hr every 15 min
Maximum: 15 mg/hr		No dose adjustment in elderly patients
EsmololBeta-blockerIV: 1–2 minIV: 10–20 minBolus: 500–1,000 mcg/kg
Initial: 50 mcg/kg/min
Titration: repeat bolus, then increase 50 mcg/kg/min every 10 min
Maximum: 200 mcg/kg/min		Contraindications: bradycardia, decompensated HF
LabetalolBeta-blocker, alpha-1 antagonistIV: 2–5 min
Peak: 5–15 min		IV: 2–6 hr
Peak: 18 hr		Bolus: 10–20 mg IV push every 10 min
IV infusion: 0.5–10 mg/min, titrate 1–2 mg/min every 2 hr
Maximum: 300 mg total		Precautions: second-/third-degree heart block, bradycardia, heart failure
Second-line agents
Phentolamine*Non-selective alpha antagonistIV: secondsIV: 15 minInitial: 5 mg IV push; may repeat every 10 min PRNUseful in catecholamine excess and clonidine withdrawal
NitroglycerinNO-dependent vasodilatorIV: 2–5 minIV: 5–10 minACS: initial 5 mcg/min, titrate 5 mcg/min every 3–5 min, max 20 mcg/min
Pulmonary edema: initial 100–200 mcg/min, titrate 50 mcg/min every 3–5 min, max 400 mcg/min		Indicated in ACS or pulmonary edema; use caution in volume-depleted patients
Sodium nitroprussideNO-dependent vasodilatorIV: secondsIV: 1–2 minInitial: 0.3–0.5 mcg/kg/min
Titration: 0.5 mcg/kg/min every 1 min
Maximum: 10 mcg/kg/min		Requires intra-arterial BP monitoring; tachyphylaxis and cyanide toxicity with prolonged use — limit treatment duration
HydralazineDirect vasodilatorIV: 10 min
IM: 20 min		IV: 1–4 hr
IM: 2–6 hr		Initial: 10–20 mg IV push; repeat every 4–6 hr PRNNot available as an IV infusion
EnalaprilatACE inhibitorIV: 15–30 minIV: 12–24 hrInitial: 1.25 mg IV over 5 min
Titration: increase by 5 mg every 6 hr as needed		Slow onset (~15 min). Contraindications: pregnancy, acute MI, bilateral renal artery stenosis

Evidence

Author (trial), yearDesignPurposeOutcome
Anderson (INTERACT pilot), 2008RCT (N=404)BP goals (SBP <140 vs <180) in acute ICH
  • Smaller mean hematoma expansion in the intensive group (13.7% vs 36.3%)
  • No significant difference in death or disability at 3 months
  • Limitation: enrolled SBP >150 mmHg; >30% received oral antihypertensives
Qureshi (ATACH-2), 2016RCT (N=1,000)BP goals (SBP 110–139 vs 140–179) in acute ICH
  • All patients received nicardipine infusion
  • No difference in death or disability at 3 months (38.7% vs 37.7%)
  • More renal adverse events within 24 hr in the intensive group (9.0% vs 4.0%)
  • Limitation: mean SBP differed by only ~10 mmHg at 2 hr (129 vs 141 mmHg)
Peacock (CLUE), 2011RCT (N=226)IV nicardipine infusion vs IV labetalol bolus for hypertensive emergency
  • Nicardipine reached target BP within 30 min more often (91.7% vs 82.5%)
  • Rescue antihypertensive use did not differ significantly within 6 hr
  • Limitation: only 63.3% had target-organ damage at randomization
Yang, 2004Small prospective RCT (N=40)IV nitroprusside vs IV nicardipine for hypertensive emergency with pulmonary edema
  • No significant difference in BP at any time point
  • No adverse events reported in either group
  • Limitation: nicardipine started at 3 mcg/kg/min (~12.5 mg/hr in a 70-kg patient)
Recent Evidence
Anderson (INTERACT2), 2013RCT (N=2,839)Intensive BP lowering (SBP <140 within 1 hr) vs guideline care in acute ICH
  • No significant reduction in the primary outcome of death or major disability
  • Ordinal analysis of modified Rankin scores favored intensive lowering
  • The pivotal phase-III evidence base for early intensive BP control in ICH
Ma (INTERACT3), 2023Cluster RCT (N=7,036)Goal-directed care bundle (incl. early intensive BP lowering) vs usual care in acute ICH
  • The care bundle improved functional outcomes (lower modified Rankin scores)
  • Supports a bundled approach to acute ICH, not BP control alone
Nam (OPTIMAL-BP), 2023RCT (N=306)Intensive (SBP <140) vs conventional (140–180) BP control after successful thrombectomy in AIS
  • Intensive BP control caused HARM — lower likelihood of functional independence at 3 months
  • Stopped early for safety; argues against intensive BP lowering after successful thrombectomy

Conclusions

  1. Select a first-line antihypertensive by the compelling indication and acute BP goal; robust outcome data comparing drug classes are lacking for most indications.
  2. Nicardipine may provide more consistent BP control than labetalol — important in acute stroke, where large BP fluctuations are believed to impair cerebral perfusion.
  3. Aggressively lowering SBP below 140 mmHg in acute ICH has not improved long-term outcomes (INTERACT2, ATACH-2) and may impair renal perfusion; after successful thrombectomy in ischemic stroke, intensive BP lowering caused harm (OPTIMAL-BP).
  4. Nicardipine provides BP control similar to nitroprusside; in acute ICH, nitroprusside use within 24 hours of presentation was associated with higher in-hospital mortality.

References

  • Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127-e248. doi:10.1016/j.jacc.2017.11.006 (co-published Hypertension. 2018;71(6):e13-e115)
  • Benken ST. Hypertensive emergencies. CCSAP. 2018 Book 1:7-30.
  • Anderson CS, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008;7(5):391-399. doi:10.1016/S1474-4422(08)70069-3
  • Qureshi AI, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage (ATACH-2). N Engl J Med. 2016;375(11):1033-1043. doi:10.1056/NEJMoa1603460
  • Peacock WF, et al. CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. Crit Care. 2011;15(3):R157. doi:10.1186/cc10289
  • Yang HJ, Kim JG, Lim YS, et al. Nicardipine versus nitroprusside infusion as antihypertensive therapy in hypertensive emergencies. J Int Med Res. 2004;32(2):118-123. doi:10.1177/147323000403200203
  • Recent evidence & current guidelines added on review (2013–2024)
  • Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage (INTERACT2). N Engl J Med. 2013;368(25):2355-2365. doi:10.1056/NEJMoa1214609
  • Ma L, Hu X, Song L, et al. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3). Lancet. 2023;402(10395):27-40. doi:10.1016/S0140-6736(23)00806-1
  • Nam HS, Kim YD, Heo J, et al. Intensive vs conventional blood pressure lowering after endovascular thrombectomy in acute ischemic stroke (OPTIMAL-BP). JAMA. 2023;330(9):832-842. doi:10.1001/jama.2023.14590
  • Bress AP, Anderson TS, Flack JM, et al. The management of elevated blood pressure in the acute care setting: a scientific statement from the American Heart Association. Hypertension. 2024;81(8):e94-e106. doi:10.1161/HYP.0000000000000238
  • Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage. Stroke. 2022;53(7):e282-e361. doi:10.1161/STR.0000000000000407
  • Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease. Circulation. 2022;146(24):e334-e482. doi:10.1161/CIR.0000000000001106
  • Wilson LM, Tang M, Robinson KA, et al. Management of inpatient elevated blood pressures: a systematic review. Ann Intern Med. 2024;177(4):497-506. doi:10.7326/M23-3251
  • Park H, Baek JH, Kim BM, et al. Blood pressure control in acute ischemic stroke after endovascular thrombectomy: a systematic review and meta-analysis. J Stroke. 2024;26(1):54-63. doi:10.5853/jos.2023.04119
Tags: SBP > 180 DBP > 120 target organ damage intravenous antihypertensives

Source PDF

HTN Emergency FINAL 12.17.20.pdf